We assembled a purpose-driven team, recruiting pioneers in oncology, gene therapy, cell therapy and gene editing to join our mission.
Founder and CEO, Board of Directors
Shailesh Maingi is Founder and CEO of Inceptor Bio. He is also the Founder and Chairman of Kineticos Life Sciences, an award-winning life sciences advisory firm. In 2019, Shailesh launched the Kineticos Disruptor Fund, investing in life science start-ups. He also co-founded the InVincible Cancer Research Fund in 2019. Shailesh serves on the Board of Directors for numerous biotechs and is Adjunct Faculty at University of North Carolina’s Kenan-Flagler School of Business. He earned his BS in Chemistry from University of North Carolina at Chapel Hill, and his MBA from Golden Gate University.
Mike Nicholson, Ph.D.
Chief Scientific Officer
Mike Nicholson is Chief Scientific Officer at Inceptor Bio. Prior to Inceptor Bio, Dr. Nicholson spent nearly 13 years at Precision BioSciences, where he held several leadership roles, including Executive Director of Scientific Operations, Vice President of R&D, and Senior Vice President of Research. Dr. Nicholson played a key role in developing Precision’s novel gene-editing platform and led research teams focused on allogeneic CAR T therapies and gene-editing-based gene therapies. Dr. Nicholson earned his BS in chemistry from SUNY Brockport, his Ph.D. in molecular biology and genetics from the Johns Hopkins School of Medicine, and carried out postdoctoral research at the University of North Carolina, Chapel Hill.
VP, Legal and Intellectual Property
Kyle Kimble is Vice President of Business Development and Licensing at Inceptor Bio. Most recently, he held the same position at Know Bio, an NC start-up, where he successfully led its Series A financing. Prior to working in the start-up environment, Kyle counseled mid-size and large pharmaceutical clients as an in-house patent attorney for Merz and Roche. Before that, he practiced patent law with Barnes & Thornburg, LLP. Kyle is a law graduate (JD) of Indiana University, having earned a Ph.D. at the University of Pittsburgh in analytical chemistry after earning an MS and a BS at Indiana University and Centre College respectively..
VP, Business Operations
Abe Maingi is Vice President of Business Operations at Inceptor Bio. Prior to his current role, he spent seven years at Kineticos Life Sciences, an award-winning life sciences advisory firm, serving in roles of increasing responsibility. He is a partner in the Kineticos Disruptor Fund and serves as a board observer for Promaxo, a medical technology company that develops and commercializes customer-centric MRI systems and MRI-based technologies. He serves as Adjunct Faculty at University of North Carolina at Chapel Hill. Abe received his BA in Business Administration from Campbell University.
Inceptor Bio’s Board Members are Shailesh Maingi (Chair), Derek Hennecke, Abe Maingi, Mark Bamforth and Dr. David Johnston. This experienced team guides the company and is also part of a broader group of industry experts acting as advisors.
David Johnston, Ph.D.
Advisor, Board of Directors
David Johnston, Ph.D., serves as Executive Vice President and global head of clinical development for PPD. He is responsible for project delivery and provides strategic direction to the company’s Phase II-IV organization in the Americas, Europe, Middle East and Africa (EMEA), and Asia-Pacific. Previously, Dr. Johnston oversaw PPD Laboratories, one of the most comprehensive global laboratory operations in the industry. Dr. Johnston earned a BA in biology from the University of North Carolina at Greensboro and a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill School of Medicine.
Advisor, Board of Directors
Derek Hennecke is a partner in the Kineticos Disruptor Fund, a fund focused on disruptive, platform technologies addressing unmet medical needs. Derek was also the Founder and CEO of Xcelience, a Florida-based contract development and manufacturing company that specialized in developing clinical Phase I-III drug product. He started the company in 2006 and sold it to a large multinational in 2016. He is currently a Board Member for The Friedreich's Ataxia Research Alliance. Derek received his BSC from the University of Alberta and his MBA from RSM Erasmus Universiteit.
Advisor, Board of Directors
Mark Bamforth is the Founder and CEO of Arranta Bio, a best-in-class microbiome contract development and manufacturing organization (CDMO). Previously, Mr. Bamforth founded Brammer Bio in 2015, a best-in-class viral vector CDMO supporting cell and gene therapies, which was acquired by Thermo Fisher Scientific in April 2019. Mark serves on the boards of Avid Bioservices, MassBio, Wentworth Institute of Technology, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.
Steve Favaloro is currently the Chief Financial Officer of Arranta Bio, a best in class microbiome CDMO. Steve also currently advises several early stage biotech companies, helping them to architect their financial and fundraising strategy. He was formerly the Chief Financial Officer at Brammer Bio, with responsibility for overseeing the financial health and information systems during a period of rapid growth and the execution of a $200M capacity expansion program. Steve received his BA in Economics from Boston College, and an MS in Finance and an MBA from the Carroll School of Management at Boston College.
Bill Mitchell is an Executive in Residence with Frazier Healthcare Partners on the Growth Buyout team. He represents Frazier on the boards of CSafe Global and Adare Pharma Solutions. Bill first joined Frazier Healthcare Partners in 2012 as part of the PCI diligence team and after successfully closing the acquisition, he led PCI until mid-2019. Mr. Mitchell returned to Frazier as a repeat Executive in Residence after serving seven years as President and CEO of PCI Pharma Services, a Frazier portfolio company. Between stints at PCI, he also served as CEO of Clondalkin Group’s North American pharma packaging operations.
Lishan Su, Ph.D.
Lishan Su is the founding scientist of Fastback Bio. Dr. Su is also Director of the Division of Virology, Pathogenesis and Cancer at University of Maryland School of Medicine. Previously, Dr. Su spent over twenty years as a faculty member in the Lineberger Comprehensive Cancer Center and as a Professor in the Department of Microbiology & Immunology at University of North Carolina-Chapel Hill. Dr. Su received his BS degree in Microbiology from Shandong University, his Ph.D. degree in Virology from Harvard University, and did his post-doctoral training in Stem Cell Biology & Immunology at Stanford University.
Nigel Walker is the Founder and Life Sciences Investor at the marketing firm “That’s Nice,” a full-service agency providing a breadth of capabilities including research, business strategy, messaging development, and consulting. With 35 years of experience in entrepreneurial business management, sales, and brand marketing, and 25 years in the pharma market, Nigel harnesses the capabilities of That’s Nice to help companies research future trends, communicate their marketing vision, and achieve business growth goals. He earned a BA with honors from London College.
Inceptor Bio’s Advisory Board is one of our core strengths, bringing together the brightest minds in the industry, with each member having already made a notable imprint on cell and gene therapeutics.
Mark Gilbert, M.D.
Mark Gilbert, M.D. is the founding Chief Medical Officer at Juno Therapeutics. Prior to joining Juno, Dr. Gilbert served as an interim Chief Medical Officer and consultant in strategic drug development and portfolio management in medical oncology for several U.S. biotechnology and pharmaceutical companies. Prior to these positions, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington in Seattle and trained in the laboratory of Dr. Phil Greenberg, one of Juno’s scientific co-founders. Dr. Gilbert earned a BS degree in biochemistry from the University of Iowa and an MD from the University of Iowa Medical School in Iowa City, Iowa.
Chris Heery, M.D.
Chris Heery is the Chief Medical Officer at Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. Prior to joining Arcellx, Dr. Heery served as Chief Medical Officer at Precision Biosciences and Bavarian Nordic where he oversaw clinical development programs in allogenic CAR-T, immune-oncology and infectious diseases portfolios. Dr. Heery has a BA in English Literature from Duke University, an MD from East Carolina University Brody School of Medicine, and completed his internal medicine residency at the University of Illinois at Chicago. He is board-certified in Medical Oncology and Internal Medicine.
Richard Snyder, Ph.D.
Richard Snyder, Ph.D., is the Vice President for Science and Technology, Pharma Services, and Viral Vector Services at Thermo Fisher Scientific. Prior to his role at Thermo Fisher Scientific, Dr. Synder was Chief Scientific Officer at Brammer Bio, an Associate Professor of Molecular Genetics and Microbiology, and Director of Biotherapeutic Programs at the University of Florida. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, received his doctoral degree in Microbiology from The State University of New York at Stony Brook, and obtained his BA in Biology from Washington University in St. Louis.
Dave Ousterout, Ph.D.
Dave Ousterout, Ph.D., is Co-Founder and Chief Scientific Officer for Locus Biosciences. Dr. Ousterout’s expertise is in protein engineering and early-stage applications of new technologies to treat human diseases. He completed his doctoral studies at Duke University in the lab of Dr. Charles Gersbach, where he developed novel gene-editing approaches for correcting mutations that cause Duchenne muscular dystrophy. Dr. Ousterout earned a B.S. in Biological & Environmental Engineering from Cornell University, an MS in Biomedical Engineering from Duke University and a Ph.D. in Biomedical Engineering from Duke University.